ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1727

BATF Represses BIM Expression to Sustain the T Cell Anergy Program

Philip Titcombe, Milagros Silva-Morales, Na Zhang and Daniel Mueller, University of Minnesota, Minneapolis, MN

Meeting: ACR Convergence 2022

Keywords: Apoptosis, Epigenetics, genomics, T Cell, transcription factor

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: T Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: T cell tolerance is essential for preventing autoimmune diseases and resolving inflammation. To maintain tolerance, CD4+ T cells recognizing self-antigens in the periphery can exert active suppression as T regulatory (Treg) cells or else enter an unresponsive state known as anergy. Recent evidence suggests that anergy occurs naturally within a subpopulation of self-reactive polyclonal CD4+ T cells and can generate precursors for Foxp3+ Treg cell differentiation.

Methods: Polyclonal CD4+ T cell subsets from C57BL/6 mice were physically sorted for the purpose of downstream sequencing-based interrogation. Anergic CD44high Foxp3– CD73high FR4high Nrp1+ T cells were compared to effector/memory (CD44high Foxp3– CD73low FR4low), Treg (Foxp3+ CD25+), and naïve (CD44low) T cell populations. Divided aliquots from the same samples were processed in parallel to generate corresponding accessible chromatin DNA (ATAC-seq) and RNA-seq information. Bioinformatic analyses were applied to identify unique transcription factor (TF) networks in the anergic T cell subpopulation. Anergy-enriched TFs were then investigated in antigen-specific tolerization systems with germline knockout mice and CRISPR-Cas9 gene editing of primary T cells.

Results: Integrated ATAC-seq and RNA-seq analysis revealed a novel TF program in anergic T cells driven by the activator protein 1 (AP-1) family member BATF (Batf). Anergy signature gene targets uniquely demonstrated open-conformation chromatin with enriched BATF consensus binding motifs and foot-printing analyses confirmed TF binding to AP-1–interferon regulatory factor (IRF) composite elements (AICEs). Remarkably, tolerized Batf-deficient T cells demonstrated reduced PD-1 (Pdcd1) expression and defective cell cycle arrest – consistent with failed anergy – and were eventually lost to clonal deletion. Mechanistically, this new deletional tolerance was driven by increased expression of the pro-apoptotic protein BIM (Bcl2l11) in the absence of BATF. Simultaneous knockdown of Batf and Bcl2l11 restored anergic T cell survival during tolerization. Finally, Batf-deficient T cells failed to give rise to a stable population of anergy-derived Foxp3+ Treg cells.

Conclusion: Anergic T cells display a unique gene-regulatory TF program driven by a BATF-containing AP-1 protein complex interacting with an IRF protein at AICE elements. Batf gene knockdown experiments suggest that BATF-dependent transactivation at checkpoint inhibitor genes such as Pdcd1 leads to the proliferative arrest of anergic cells. Furthermore, BATF upregulation during anergy induction is essential to suppress the expression of BIM and ensure the survival of anergic T cells and anergy-derived Foxp3+ Tregs.

Supporting image 1


Disclosures: P. Titcombe, None; M. Silva-Morales, None; N. Zhang, None; D. Mueller, None.

To cite this abstract in AMA style:

Titcombe P, Silva-Morales M, Zhang N, Mueller D. BATF Represses BIM Expression to Sustain the T Cell Anergy Program [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/batf-represses-bim-expression-to-sustain-the-t-cell-anergy-program/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/batf-represses-bim-expression-to-sustain-the-t-cell-anergy-program/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology